var data={"title":"Amitriptyline: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Amitriptyline: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5618?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=amitriptyline-patient-drug-information\" class=\"drug drug_patient\">see &quot;Amitriptyline: Patient drug information&quot;</a> and <a href=\"topic.htm?path=amitriptyline-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Amitriptyline: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708615\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Suicidality and antidepressant drugs:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Antidepressants increased the risk compared with placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of major depressive disorder (MDD) and other psychiatric disorders. Anyone considering the use of amitriptyline in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared with placebo in adults older than 24 years; there was a reduction in risk with antidepressants compared with placebo in adults 65 years and older. Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. Amitriptyline is not approved for use in pediatric patients.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F46519250\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Elavil [DSC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133739\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Apo-Amitriptyline;</li>\n      <li>Bio-Amitriptyline;</li>\n      <li>Elavil;</li>\n      <li>Levate;</li>\n      <li>Novo-Triptyn;</li>\n      <li>PMS-Amitriptyline</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133787\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antidepressant, Tricyclic (Tertiary Amine)</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133743\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Depression:</b> Oral: Initial: 25 to 50 mg daily single dose at bedtime or in divided doses; initial doses of 100 mg daily may be considered in hospitalized patients. Gradually increase dose to 100 to 300 mg daily (APA 2010; Bauer 2013).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chronic pain management (off-label use):</b> Oral: Initial: 25 to 50 mg at bedtime; may increase as tolerated to 150 mg daily (McQuay 1992; Pilowsky 1982; Zitman 1990).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Diabetic neuropathy (off-label use):</b> Oral: 25 to 100 mg daily (Bril, 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Fibromyalgia (off-label use):</b> Oral: 10 to 50 mg daily at bedtime; <b>Note:</b> Higher doses (50 mg) may not be more effective than lower doses (Carette 1994; H&auml;user 2009; H&auml;user 2012; Macfarlane 2017; Nishishinya 2008).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Insomnia (off-label use):</b> Oral: 25 to 100 mg daily at bedtime in healthy adults, and up to 150 mg daily in patients with depression (Kerkhofs 1990; Srisurapanont 1998). Additional data may be necessary to further define the role of amitriptyline in this condition.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Interstitial cystitis (bladder pain syndrome) (off-label use):</b> Oral: 10 to 25 mg daily titrated weekly over several weeks to a target dose of 75 to 100 mg as tolerated (AUA [Hanno 2014]; Foster 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Irritable bowel syndrome (off-label use):</b> Oral: Initial: 10 to 25 mg daily at bedtime; may increase dose based on response and tolerability up to 75 mg (Rajagopalan 1998; Vahedi 2008).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Migraine prophylaxis (off-label use):</b> Oral: Initial: 10 to 25 mg at bedtime; increase at weekly increments of 10 to 25 mg daily based on response and tolerability up to 150 mg daily (Couch 1976; Dodick 2009; Evers 2009; Keskinbora 2008).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Postherpetic neuralgia (off-label use):</b> Oral: Initial: 10 to 25 mg, given once daily at bedtime or divided into twice daily doses; consider starting with 10 to 12.5 mg once daily at bedtime for patients older than 65 years. Increase dose based on response and tolerability in increments of 10 to 25 mg every 2 to 7 days up to 200 mg/day; one study reported no benefit with doses greater than 100 mg daily (Graff-Radford 2000; Max 1988; Rowbotham 2005; Watson 1982; Watson 1992; Watson 1998).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Post-traumatic stress disorder (PTSD) (off-label use):</b> Oral: Initial: 50 mg daily; increase at 25 mg increments as tolerated to 100 mg within the first week; increase to 150 mg daily, then 200 mg daily before the end of 2 weeks; increase further if necessary and tolerated (Davidson 1990).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Sialorrhea (off-label use):</b> Oral: Initial: 10 to 25 mg once daily at bedtime or 10 mg 3 times daily. May increase dose based on response and tolerability up to 100 mg/day (Andersen 2012; Praharaj 2007; Sinha 2016, Squires 2012). Additional data may be necessary to define the role of amitriptyline in this condition.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Discontinuation of therapy:</b> Upon discontinuation of antidepressant therapy, gradually taper the dose to minimize the incidence of withdrawal symptoms and allow for the detection of re-emerging symptoms. Evidence supporting ideal taper rates is limited. APA and NICE guidelines suggest tapering therapy over at least several weeks with consideration to the half-life of the antidepressant; antidepressants with a shorter half-life may need to be tapered more conservatively. In addition for long-term treated patients, WFSBP guidelines recommend tapering over 4 to 6 months. If intolerable withdrawal symptoms occur following a dose reduction, consider resuming the previously prescribed dose and/or decrease dose at a more gradual rate (APA 2010; Bauer 2002; Haddad 2001; NCCMH 2010; Schatzberg, 2006; Shelton, 2001; Warner, 2006).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>MAO inhibitor recommendations:</b> <i>Switching to or from an MAO inhibitor antidepressant:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Allow 14 days to elapse between discontinuing an MAO inhibitor intended to treat depression and initiation of amitriptyline.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Allow 14 days to elapse between discontinuing amitriptyline and initiation of an MAO inhibitor intended to treat depression.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133763\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=amitriptyline-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Amitriptyline: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Chronic pain management (off-label use):</b> Oral: Initial: 0.1 mg/kg/day at bedtime, may advance as tolerated over 2-3 weeks to 0.5-2 mg/kg/day at bedtime (APS [Miaskowski, 2008]; Freidrichsdorf, 2007; Kliegman, 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Depressive disorders:</b>  <i>Adolescents:</i>  Usual dosage (recommended by the manufacturer): 10 mg three times daily and 20 mg at bedtime. In general, lower doses are recommended for adolescent patients. <b>Note:</b> Controlled clinical trials have not shown tricyclic antidepressants to be superior to placebo for the treatment of depression in children and adolescents; not recommended as first-line medication; may be beneficial for patient with comorbid conditions (Birmaher, 2007; Dopheide, 2006; Wagner, 2005).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Migraine prophylaxis (off-label use):</b> Oral: Initial: 0.25 mg/kg/day, given at bedtime; increase dose by 0.25 mg/kg/day every 2 weeks to 1 mg/kg/day. Reported dosing range: 0.2-1.7 mg/kg/day (Hershey, 2000). </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Discontinuation of therapy:</b> Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>MAO inhibitor recommendations:</b> Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133744\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Depression:</b> Oral: Usual dosage (recommended by the manufacturer): 10 mg 3 times daily and 20 mg at bedtime.  In general, lower doses are recommended for elderly patients</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Postherpetic neuralgia (off-label use):</b> Oral: Initial: 10 to 12.5 mg, given once daily at bedtime or divided into twice daily doses. Increase dose based on response and tolerability in increments of 10 to 25 mg every 2 to 7 days up to 200 mg/day; one study reported no benefit with doses greater than 100 mg daily (Graff-Radford 2000; Max 1988; Rowbotham 2005; Watson 1982; Watson 1992; Watson 1998). </p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">\n      <b>Discontinuation of therapy:</b> Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>MAO inhibitor recommendations:</b> Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133745\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in manufacturer&rsquo;s labeling; however, renally eliminated; use with caution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133746\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in manufacturer&rsquo;s labeling; however, hepatically metabolized; use with caution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133713\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Elavil: 25 mg [DSC] [contains fd&amp;c blue #2 aluminum lake, fd&amp;c yellow #10 aluminum lake]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10 mg, 25 mg, 50 mg, 75 mg, 100 mg, 150 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133696\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7874280\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and at the following website, must be dispensed with this medication:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Antidepressant medications: <a target=\"_blank\" href=\"https://www.fda.gov/downloads/drugs/drugsafety/ucm088660.pdf&amp;token=8RYIFfyLhIBYEqeX7m6uPPQEVrZ0DF7DWCCLO7W6cf9/+Q1J8etDBVp+C7h2tFOvlFDpOnb8grs5FgzfpCyYCQ==&amp;TOPIC_ID=8605\" target=\"_blank\">https://www.fda.gov/downloads/drugs/drugsafety/ucm088660.pdf</a></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23890541\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: Administer higher doses preferably at late afternoon or as bedtime doses to minimize daytime sedation. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133717\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Depression:</b> Treatment of depression</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25475031\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Chronic pain management; Diabetic neuropathy; Fibromyalgia syndrome; Insomnia (adults); Interstitial cystitis (bladder pain syndrome); Irritable bowel syndrome; Migraine prophylaxis (adults); Migraine prophylaxis (children/adolescents); Postherpetic neuralgia; Post-traumatic stress disorder; Sialorrhea (drooling) in adults</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133796\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Amitriptyline may be confused with aminophylline, imipramine, nortriptyline</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Elavil may be confused with Aldoril, Eldepryl, enalapril, Equanil, Plavix</p>\n        <p style=\"text-indent:2em;margin-right:4em;\">Elavil may be confused with Elavil OTC (an over-the-counter sleep aid containing melatonin, valerian root, and vitamins).</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Geriatric Patients: High-Risk Medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Beers Criteria: Amitriptyline (alone or in combination) is identified in the Beers Criteria as a potentially inappropriate medication to be avoided in patients 65 years and older (independent of diagnosis or condition) due to its strong anticholinergic properties and potential for sedation and orthostatic hypotension. Because of their association with falls and fractures, tricyclic antidepressants (TCAs) are to be avoided in patients 65 years and older with a history of falls or fractures. In addition, use TCAs with caution due to their potential to cause or exacerbate syndrome of inappropriate antidiuretic hormone secretion (SIADH) or hyponatremia; monitor sodium closely with initiation or dosage adjustments in older adults (Beers Criteria [AGS 2015]).</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Pharmacy Quality Alliance (PQA): Amitriptyline (alone or in combination) is identified as a high-risk medication in patients 65 years and older on the PQA&rsquo;s, Use of High-Risk Medications in the Elderly (HRM) performance measure, a safety measure used by the Centers for Medicare and Medicaid Services (CMS) for Medicare plans.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133703\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Anticholinergic effects may be pronounced; moderate to marked sedation can occur (tolerance to these effects usually occurs).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">Frequency not defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cardiovascular: Atrioventricular conduction disturbance, cardiac arrhythmia, cardiomyopathy (rare), cerebrovascular accident, ECG changes (nonspecific), edema, facial edema, heart block, hypertension, myocardial infarction, orthostatic hypotension, palpitations, syncope, tachycardia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Anxiety, ataxia, cognitive dysfunction, coma, confusion, delusions, disorientation, dizziness, drowsiness, drug withdrawal (nausea, headache, malaise, irritability, restlessness, dream and sleep disturbance, mania [rare], and hypomania [rare]), dysarthria, EEG pattern changes, excitement, extrapyramidal reaction (including abnormal involuntary movements and tardive dyskinesia), fatigue, hallucination, headache, hyperpyrexia, insomnia, lack of concentration, nightmares, numbness, paresthesia, peripheral neuropathy, restlessness, sedation, seizure, tingling of extremities</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dermatologic: Allergic skin rash, alopecia, diaphoresis, skin photosensitivity, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Endocrine &amp; metabolic: Altered serum glucose, decreased libido, galactorrhea, gynecomastia, increased libido, SIADH, weight gain, weight loss</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Ageusia, anorexia, constipation, diarrhea, melanoglossia, nausea, paralytic ileus, parotid gland enlargement, stomatitis, unpleasant taste, vomiting, xerostomia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Genitourinary: Breast hypertrophy, impotence, testicular swelling, urinary frequency, urinary retention, urinary tract dilation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hematologic &amp; oncologic: Bone marrow depression (including agranulocytosis, leukopenia, and thrombocytopenia), eosinophilia, purpura</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hepatic: Hepatic failure, hepatitis (rare; including altered liver function and jaundice)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hypersensitivity: Tongue edema</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Neuromuscular &amp; skeletal: Lupus-like syndrome, tremor, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Ophthalmic: Accommodation disturbance, blurred vision, increased intraocular pressure, mydriasis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Otic: Tinnitus</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Postmarketing and/or case reports: Angle-closure glaucoma, neuroleptic malignant syndrome (rare; Stevens, 2008), serotonin syndrome (rare)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133721\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;\">Hypersensitivity to amitriptyline or any component of the formulation; coadministration with or within 14 days of MAOIs; coadministration with cisapride; acute recovery phase following myocardial infarction</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Documentation of allergenic cross-reactivity for tricyclic antidepressants is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133700\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Major psychiatric warnings:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Suicidal thinking/behavior: <b>[US Boxed Warning]: Antidepressants increase the risk of suicidal thinking and behavior in children, adolescents, and young adults (18 to 24 years of age) with major depressive disorder (MDD) and other psychiatric disorders;</b> consider risk prior to prescribing. Short-term studies did not show an increased risk in patients &gt;24 years of age and showed a decreased risk in patients &ge;65 years. Closely monitor patients for clinical worsening, suicidality, or unusual changes in behavior, particularly during the initial 1-2 months of therapy or during periods of dosage adjustments (increases or decreases); the patient&rsquo;s family or caregiver should be instructed to closely observe the patient and communicate condition with healthcare provider. A medication guide concerning the use of antidepressants should be dispensed with each prescription. <b>Amitriptyline is not FDA-approved for use in children.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; The possibility of a suicide attempt is inherent in major depression and may persist until remission occurs. Worsening depression and severe abrupt suicidality that are not part of the presenting symptoms may require discontinuation or modification of drug therapy. Use caution in high-risk patients during initiation of therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Prescriptions should be written for the smallest quantity consistent with good patient care. The patient's family or caregiver should be alerted to monitor patients for the emergence of suicidality and associated behaviors such as anxiety, agitation, panic attacks, insomnia, irritability, hostility, impulsivity, akathisia, hypomania, and mania; patients should be instructed to notify their healthcare provider if any of these symptoms or worsening depression or psychosis occur.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anticholinergic effects: May cause anticholinergic effects (constipation, xerostomia, blurred vision, urinary retention); use with caution in patients with decreased gastrointestinal motility, increased intraocular pressure (IOP), narrow-angle glaucoma, paralytic ileus, urinary retention, BPH, xerostomia, or visual problems. The degree of anticholinergic blockade produced by this agent is high relative to other antidepressants.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks that require mental alertness (eg, operating machinery or driving).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Fractures: Bone fractures have been associated with antidepressant treatment. Consider the possibility of a fragility fracture if an antidepressant-treated patient presents with unexplained bone pain, point tenderness, swelling, or bruising (Rabenda 2013; Rizzoli 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hematologic effects: TCAs may rarely cause bone marrow suppression; monitor for any signs of infection and obtain CBC if symptoms (eg, fever, sore throat) evident.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ocular effects: May cause mild pupillary dilation which in susceptible individuals can lead to an episode of narrow-angle glaucoma. Consider evaluating patients who have not had an iridectomy for narrow-angle glaucoma risk factors.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Orthostatic hypotension: May cause orthostatic hypotension (risk is very high relative to other antidepressants); use with caution in patients at risk of this effect or in those who would not tolerate transient hypotensive episodes (cerebrovascular disease, cardiovascular disease, hypovolemia, or concurrent medication use which may predispose to hypotension/bradycardia). Therapy is relatively contraindicated in patients with symptomatic hypotension.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution in patients with a history of cardiovascular disease (including previous MI, stroke, tachycardia, or conduction abnormalities); the risk of conduction abnormalities with this agent is high relative to other antidepressants. Heart block may be precipitated in patients with preexisting conduction system disease and use is relatively contraindicated in patients with conduction abnormalities. In a scientific statement from the American Heart Association, amitriptyline has been determined to be an agent that may exacerbate underlying myocardial dysfunction (magnitude: moderate) (AHA [Page 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Diabetes: Use with caution in patients with diabetes mellitus; may alter glucose regulation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Mania/hypomania: May precipitate a shift to mania or hypomania in patients with bipolar disorder. Patients presenting with depressive symptoms should be screened for bipolar disorder, including details regarding family history of suicide, bipolar disorder, and depression. <b>Amitriptyline is not FDA approved for the treatment of bipolar depression. </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizure disorder: Use with caution in patients at risk of seizures, including those with a history of seizures, head trauma, brain damage, alcoholism, or concurrent therapy with medications which may lower seizure threshold.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Discontinuation syndrome: Abrupt discontinuation or interruption of antidepressant therapy has been associated with a discontinuation syndrome. Symptoms arising may vary with antidepressant however commonly include nausea, vomiting, diarrhea, headaches, light-headedness, dizziness, diminished appetite, sweating, chills, tremors, paresthesias, fatigue, somnolence, and sleep disturbances (eg, vivid dreams, insomnia). Less common symptoms include electric shock-like sensations, cardiac arrhythmias (more common with tricyclic antidepressants), myalgias, parkinsonism, arthralgias, and balance difficulties. Psychological symptoms may also emerge such as agitation, anxiety, akathisia, panic attacks, irritability, aggressiveness, worsening of mood, dysphoria, mood lability, hyperactivity, mania/hypomania, depersonalization, decreased concentration, slowed thinking, confusion, and memory or concentration difficulties. Greater risks for developing a discontinuation syndrome have been associated with antidepressants with shorter half-lives, longer durations of treatment, and abrupt discontinuation. For antidepressants of short or intermediate half-lives, symptoms may emerge within 2-5 days after treatment discontinuation and last 7-14 days (APA, 2010; Fava, 2006; Haddad, 2001; Shelton, 2001; Warner, 2006).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Electroconvulsive therapy: May increase the risks associated with electroconvulsive therapy; consider discontinuing, when possible, prior to ECT treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Surgery: Recommended by the manufacturer to discontinue prior to elective surgery; risks exist for drug interactions with anesthesia and for cardiac arrhythmias. However, definitive drug interactions have not been widely reported in the literature and continuation of tricyclic antidepressants is generally recommended as long as precautions are taken to reduce the significance of any adverse events that may occur. Norepinephrine should be considered the vasopressor of choice for TCA-related hypotension (Pass, 2004). Therapy should not be abruptly discontinued in patients receiving high doses for prolonged periods.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133781\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP1A2 (minor), CYP2B6 (minor), CYP2C19 (minor), CYP2C9 (minor), CYP2D6 (major), CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP2C9 (weak), CYP2E1 (weak)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133705\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8605&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">AbobotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Acetylcholinesterase Inhibitors: May diminish the therapeutic effect of Anticholinergic Agents. Anticholinergic Agents may diminish the therapeutic effect of Acetylcholinesterase Inhibitors.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alpha-/Beta-Agonists (Direct-Acting): Tricyclic Antidepressants may enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting).  Management: Avoid, if possible, the use of direct-acting alpha-/beta-agonists in patients receiving tricyclic antidepressants. If combined, monitor for evidence of increased pressor effects and consider reductions in initial dosages of the alpha-/beta-agonist.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alpha1-Agonists: Tricyclic Antidepressants may enhance the vasopressor effect of Alpha1-Agonists. Tricyclic Antidepressants may diminish the vasopressor effect of Alpha1-Agonists. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alpha2-Agonists: Tricyclic Antidepressants may diminish the antihypertensive effect of Alpha2-Agonists. <b> Exceptions: </b>Apraclonidine; Brimonidine (Ophthalmic).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alpha2-Agonists (Ophthalmic): Tricyclic Antidepressants may diminish the therapeutic effect of Alpha2-Agonists (Ophthalmic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Altretamine: May enhance the orthostatic hypotensive effect of Tricyclic Antidepressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amantadine: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amezinium: May enhance the adverse/toxic effect of Tricyclic Antidepressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amifampridine: May diminish the anticholinergic effect of Anticholinergic Agents. Anticholinergic Agents may diminish the therapeutic effect of Amifampridine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amifampridine: May enhance the adverse/toxic effect of Tricyclic Antidepressants. Specifically, both drugs have the potential to decrease the seizure threshold, possibly increasing the risk for seizures. Tricyclic Antidepressants may diminish the therapeutic effect of Amifampridine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphetamines: Tricyclic Antidepressants may enhance the stimulatory effect of Amphetamines. Tricyclic Antidepressants may also potentiate the cardiovascular effects of Amphetamines. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anticholinergic Agents: May enhance the adverse/toxic effect of other Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antiemetics (5HT3 Antagonists): May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents: Serotonin Modulators may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aspirin: Tricyclic Antidepressants (Tertiary Amine) may enhance the antiplatelet effect of Aspirin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Asunaprevir: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barbiturates: May increase the metabolism of Tricyclic Antidepressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Beta2-Agonists: Tricyclic Antidepressants may enhance the adverse/toxic effect of Beta2-Agonists. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromopride: May enhance the adverse/toxic effect of Tricyclic Antidepressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of other CNS depressants, and avoiding such drugs in patients at high risk of buprenorphine overuse/self-injection. Initiate buprenorphine patches (Butrans brand) at 5 mcg/hr in adults when used with other CNS depressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BuPROPion: May decrease the metabolism of Tricyclic Antidepressants. Management: Seek alternatives when possible. Monitor patients receiving these combinations closely for increased serum concentrations (when testing is available) and toxic effects of the tricyclic antidepressant.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabis: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CarBAMazepine: May decrease the serum concentration of Tricyclic Antidepressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloral Betaine: May enhance the adverse/toxic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Monitor closely for evidence of excessive CNS depression. The chlormethiazole labeling states that an appropriately reduced dose should be used if such a combination must be used.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cimetidine: May decrease the metabolism of Tricyclic Antidepressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cimetropium: Anticholinergic Agents may enhance the anticholinergic effect of Cimetropium. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cinacalcet: May increase the serum concentration of Tricyclic Antidepressants. Management: Seek alternatives when possible. If these combinations are used, monitor closely for increased effects/toxicity and/or elevated serum concentrations (when testing is available) of the tricyclic antidepressant.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cisapride: Amitriptyline may enhance the arrhythmogenic effect of Cisapride. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Citalopram: Tricyclic Antidepressants may enhance the adverse/toxic effect of Citalopram. Tricyclic Antidepressants may increase the serum concentration of Citalopram. Citalopram may increase the serum concentration of Tricyclic Antidepressants.  Management: Consider alternatives to this combination when possible.  Monitor for adverse effects of tricyclic antidepressants (TCAs), including serotonin syndrome and QT-interval prolongation, when a TCA is being used in combination with citalopram.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cobicistat: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2D6 Inhibitors (Moderate): May decrease the metabolism of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2D6 Inhibitors (Strong): May decrease the metabolism of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dapoxetine: May enhance the adverse/toxic effect of Serotonin Modulators.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Darunavir: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Desmopressin: Tricyclic Antidepressants may enhance the adverse/toxic effect of Desmopressin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dexmethylphenidate: May enhance the adverse/toxic effect of Tricyclic Antidepressants. Dexmethylphenidate may increase the serum concentration of Tricyclic Antidepressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dimethindene (Topical): May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Doxylamine: May enhance the CNS depressant effect of CNS Depressants. Management: The manufacturer of Diclegis (doxylamine/pyridoxine), intended for use in pregnancy, specifically states that use with other CNS depressants is  not recommended.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronedarone: Tricyclic Antidepressants may enhance the arrhythmogenic effect of Dronedarone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DULoxetine: May enhance the serotonergic effect of Tricyclic Antidepressants. This could result in serotonin syndrome. DULoxetine may decrease the metabolism of Tricyclic Antidepressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eluxadoline: Anticholinergic Agents may enhance the constipating effect of Eluxadoline. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Escitalopram: Tricyclic Antidepressants may enhance the adverse/toxic effect of Escitalopram. Escitalopram may increase the serum concentration of Tricyclic Antidepressants.  Management: Consider alternatives to this combination when possible.  Monitor for adverse effects of tricyclic antidepressants (TCAs), including serotonin syndrome and QT-interval prolongation, when a TCA is being used in combination with escitalopram.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fluconazole: Amitriptyline may enhance the QTc-prolonging effect of Fluconazole. Fluconazole may increase the serum concentration of Amitriptyline. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flunitrazepam: CNS Depressants may enhance the CNS depressant effect of Flunitrazepam. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">FLUoxetine: May enhance the adverse/toxic effect of Tricyclic Antidepressants. FLUoxetine may increase the serum concentration of Tricyclic Antidepressants. Management: Consider alternatives to this combination when possible.  Monitor for adverse effects of tricyclic antidepressants (TCAs), including serotonin syndrome and QT-interval prolongation, when a TCA is being used in combination with fluoxetine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">FluvoxaMINE: May enhance the adverse/toxic effect of Tricyclic Antidepressants. FluvoxaMINE may increase the serum concentration of Tricyclic Antidepressants. Management: Consider alternatives to this combination when possible.  Monitor for adverse effects of tricyclic antidepressants (TCAs), including serotonin syndrome and QT-interval prolongation, when a TCA is being used in combination with fluvoxamine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal Agents (Prokinetic): Anticholinergic Agents may diminish the therapeutic effect of Gastrointestinal Agents (Prokinetic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Glucagon: Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Glycopyrrolate (Oral Inhalation): Anticholinergic Agents may enhance the anticholinergic effect of Glycopyrrolate (Oral Inhalation). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Guanethidine: Tricyclic Antidepressants may diminish the therapeutic effect of Guanethidine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HYDROcodone: CNS Depressants may enhance the CNS depressant effect of HYDROcodone.  Management: Avoid concomitant use of hydrocodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Imatinib: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iobenguane I 123: Tricyclic Antidepressants may diminish the therapeutic effect of Iobenguane I 123. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iohexol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iohexol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iohexol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic anticonvulsants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iomeprol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iomeprol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iomeprol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic anticonvulsants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iopamidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iopamidol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iopamidol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic anticonvulsants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Itopride: Anticholinergic Agents may diminish the therapeutic effect of Itopride. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Kava Kava: May enhance the adverse/toxic effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levosulpiride: Anticholinergic Agents may diminish the therapeutic effect of Levosulpiride. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Linezolid: May enhance the serotonergic effect of Tricyclic Antidepressants. This could result in serotonin syndrome.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lithium: May enhance the neurotoxic effect of Tricyclic Antidepressants. Management: This combination should be undertaken with great caution.  When combined treatment is clinically indicated, monitor closely for signs of serotonin toxicity/serotonin syndrome.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metaxalone: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylene Blue: Tricyclic Antidepressants may enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylene Blue: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylphenidate: May enhance the adverse/toxic effect of Tricyclic Antidepressants. Methylphenidate may increase the serum concentration of Tricyclic Antidepressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylphenidate: May enhance the adverse/toxic effect of Serotonin Modulators. Specifically, the risk of serotonin syndrome or serotonin toxicity may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metoclopramide: May enhance the adverse/toxic effect of Tricyclic Antidepressants. Management: Seek alternatives to this combination when possible. Monitor patients receiving metoclopramide with tricyclic antidepressants for signs of extrapyramidal symptoms, neuroleptic malignant syndrome, and serotonin syndrome.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetyroSINE: May enhance the adverse/toxic effect of Tricyclic Antidepressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mianserin: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Minocycline: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mirabegron: Anticholinergic Agents may enhance the adverse/toxic effect of Mirabegron. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Monoamine Oxidase Inhibitors: May enhance the serotonergic effect of Tricyclic Antidepressants. This may cause serotonin syndrome.  While methylene blue and linezolid are expected to interact via this mechanism, management recommendations differ from other monoamine oxidase inhibitors.  Refer to monographs specific to those agents for details.<b> Exceptions: </b>Linezolid; Methylene Blue; Tedizolid.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nabilone: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicorandil: Tricyclic Antidepressants may enhance the hypotensive effect of Nicorandil. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitroglycerin: Anticholinergic Agents may decrease the absorption of Nitroglycerin. Specifically, anticholinergic agents may decrease the dissolution of sublingual nitroglycerin tablets, possibly impairing or slowing nitroglycerin absorption. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective): Tricyclic Antidepressants (Tertiary Amine) may enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents (Nonselective): Tricyclic Antidepressants (Tertiary Amine) may enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents (Nonselective). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OnabotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Opioid Analgesics: CNS Depressants may enhance the CNS depressant effect of Opioid Analgesics.  Management: Avoid concomitant use of opioid analgesics and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oxatomide: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oxomemazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE.  Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Panobinostat: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Management: Avoid concurrent use of sensitive CYP2D6 substrates when possible, particularly those substrates with a narrow therapeutic index.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PARoxetine: May enhance the adverse/toxic effect of Tricyclic Antidepressants. PARoxetine may increase the serum concentration of Tricyclic Antidepressants. Management: Consider alternatives to this combination when possible.  Monitor for adverse effects of tricyclic antidepressants (TCAs), including serotonin syndrome and QT-interval prolongation, when a TCA is being used in combination with paroxetine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Peginterferon Alfa-2b may increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Perhexiline: CYP2D6 Substrates (High risk with Inhibitors) may increase the serum concentration of Perhexiline. Perhexiline may increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Piribedil: CNS Depressants may enhance the CNS depressant effect of Piribedil. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pitolisant: Tricyclic Antidepressants may diminish the therapeutic effect of Pitolisant. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Potassium Chloride: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride.  Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Potassium Citrate: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Citrate. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pramlintide: May enhance the anticholinergic effect of Anticholinergic Agents. These effects are specific to the GI tract.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protease Inhibitors: May increase the serum concentration of Tricyclic Antidepressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Highest Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Moderate Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QuiNIDine: Tricyclic Antidepressants may enhance the QTc-prolonging effect of QuiNIDine. QuiNIDine may increase the serum concentration of Tricyclic Antidepressants. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ramosetron: Anticholinergic Agents may enhance the constipating effect of Ramosetron. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RimabotulinumtoxinB: Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rufinamide: May enhance the adverse/toxic effect of CNS Depressants. Specifically, sleepiness and dizziness may be enhanced.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin.  Management: Avoid concomitant use of anticholinergic agents and secretin. Discontinue anticholinergic agents at least 5 half-lives prior to administration of secretin.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur.<b> Exceptions: </b>Nicergoline; Tedizolid.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sertraline: May enhance the adverse/toxic effect of Tricyclic Antidepressants. Sertraline may increase the serum concentration of Tricyclic Antidepressants. Management: Consider alternatives to this combination when possible.  Monitor for adverse effects of tricyclic antidepressants (TCAs), including serotonin syndrome and QT-interval prolongation, when a TCA is being used in combination with sertraline.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Phosphates: Tricyclic Antidepressants may enhance the adverse/toxic effect of Sodium Phosphates. Specifically, the risk of seizure and/or loss of consciousness may be increased in patients with significant sodium phosphate induced fluid/electrolyte abnormalities. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">St John's Wort: May increase the metabolism of Tricyclic Antidepressants. The risk of serotonin syndrome may theoretically be increased.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sulfonylureas: Cyclic Antidepressants may enhance the hypoglycemic effect of Sulfonylureas. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Suvorexant: CNS Depressants may enhance the CNS depressant effect of Suvorexant.  Management: Dose reduction of suvorexant and/or any other CNS depressant may be necessary.  Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tapentadol: May enhance the CNS depressant effect of CNS Depressants. Management: Avoid concomitant use of tapentadol and benzodiazepines or other CNS depressants when possible. These agents should only be combined if alternative treatment options are inadequate. If combined, limit the dosages and duration of each drug.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tedizolid: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Terbinafine (Systemic): May increase the serum concentration of Amitriptyline. Management: Monitor for increased effects/toxicity of amitriptyline during concomitant administration with terbinafine. Reduced dosages of amitriptyline may be needed.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetrahydrocannabinol: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thalidomide: CNS Depressants may enhance the CNS depressant effect of Thalidomide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiazide and Thiazide-Like Diuretics: Anticholinergic Agents may increase the serum concentration of Thiazide and Thiazide-Like Diuretics. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thyroid Products: May enhance the arrhythmogenic effect of Tricyclic Antidepressants. Thyroid Products may enhance the stimulatory effect of Tricyclic Antidepressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tiotropium: Anticholinergic Agents may enhance the anticholinergic effect of Tiotropium. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Topiramate: May enhance the CNS depressant effect of Amitriptyline. Topiramate may increase serum concentrations of the active metabolite(s) of Amitriptyline. Topiramate may increase the serum concentration of Amitriptyline.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trimeprazine: May enhance the CNS depressant effect of CNS Depressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Umeclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Valproate Products: May increase the serum concentration of Tricyclic Antidepressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Tricyclic Antidepressants may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Yohimbine: Tricyclic Antidepressants may increase the serum concentration of Yohimbine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem adult dose to 1.75 mg for  men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133708\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133724\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in some animal reproduction studies. Amitriptyline crosses the human placenta; CNS effects, limb deformities, and developmental delay have been noted in case reports (causal relationship not established). Tricyclic antidepressants may be associated with irritability, jitteriness, and convulsions (rare) in the neonate (Yonkers 2009). Crying, constipation, problems with urinating, and nausea may also occur in neonates exposed during pregnancy (Larsen 2015).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The ACOG recommends that therapy for depression during pregnancy be individualized; treatment should incorporate the clinical expertise of the mental health clinician, obstetrician, primary health care provider, and pediatrician (ACOG 2008). According to the American Psychiatric Association (APA), the risks of medication treatment should be weighed against other treatment options and untreated depression. For women who discontinue antidepressant medications during pregnancy and who may be at high risk for postpartum depression, the medications can be restarted following delivery (APA 2010). Treatment algorithms have been developed by the ACOG and the APA for the management of depression in women prior to conception and during pregnancy (Yonkers 2009). Tricyclic antidepressants are not the preferred therapy for depression in pregnant women but may be helpful when agitation is also present. If a TCA is needed, amitriptyline one of the preferred agents. Maternal serum concentrations should be monitored during pregnancy (Larsen 2015; Yonkers 2009). Although not a first-line agent, amitriptyline may be used for the treatment of post-traumatic stress disorder in pregnant women (Bandelow 2008). Migraine prophylaxis should be avoided during pregnancy; if needed, amitriptyline may be used if other agents are ineffective or contraindicated (Pringsheim 2012).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Pregnant women exposed to antidepressants during pregnancy are encouraged to enroll in the National Pregnancy Registry for Antidepressants (NPRAD). Women 18 to 45 years of age or their health care providers may contact the registry by calling 844-405-6185. Enrollment should be done as early in pregnancy as possible.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133725\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Amitriptyline and the metabolite nortriptyline are present in breast milk (Bader 1980).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The relative infant dose (RID) of amitriptyline is 1.2 % when calculated using the highest breast milk concentration located and compared to a weight-adjusted maternal dose of 175 mg/day. In general, breastfeeding is considered acceptable when the RID is &lt;10% (Anderson 2016; Ito 2000). Using the highest milk concentration (197 ng/mL), the estimated daily infant dose via breast milk is 0.03 mg/kg/day. This milk concentration was obtained following maternal administration of oral amitriptyline 175 mg/day for ~28 days (Yoshida 1997). In a review article which included six mother/infant pairs, following maternal use of amitriptyline 75 to 175 mg/day, the estimated exposure to the breastfeeding infant was calculated as 0.2% to 1.9% of the weight-adjusted maternal dose (additional detail not provided) (Fortinguerra 2009). Very small amounts of amitriptyline can be detected in the plasma and urine of breastfeeding infants (Yoshida 1997). It should be noted that actual milk concentrations of tricyclic antidepressants are generally related to maternal serum concentration and vary by fat content of breast milk; the level of detection varies greatly by assay method (Yoshida 1997).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Most sources have not reported adverse events in infants exposed to amitriptyline via breast milk (Fortinguerra 2009; Larsen 2015; Yoshida 1997). However, in a case report, severe sedation with associated poor feeding was observed in a breastfed infant (~15 days old) following the initiation of amitriptyline 10 mg/day in the mother. Symptoms in the infant decreased within 24 hours and resolved within 48 hours after the maternal dose was discontinued. Once amitriptyline was reinitiated in the mother, symptoms in the infant returned (Uguz 2017).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Infants of mothers using psychotropic medications should be monitored daily for changes in sleep, feeding patterns, and behavior (Bauer 2013) as well as infant growth and neurodevelopment (Sriraman 2015).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Tricyclic antidepressants are not the preferred therapy for depression in breastfeeding women. However, if a TCA is needed, amitriptyline is one of the agents with information available (Larsen 2015). A woman already stabilized on a TCA during pregnancy may continue that medication while breastfeeding (Sriraman 2015). Migraine prophylaxis should be avoided in women who are breastfeeding; if needed, amitriptyline may be used if other agents are ineffective or contraindicated (Pringsheim 2012). The WHO considers amitriptyline to be compatible with breastfeeding in doses &le;150 mg/day (WHO 2002). Due to the potential for serious adverse reactions in the breastfed infant, the manufacturer recommends a decision be made whether to discontinue breastfeeding or to discontinue the drug, taking into account the importance of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133710\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Evaluate mental status, suicide ideation (especially at the beginning of therapy or when doses are increased or decreased); anxiety, social functioning, mania, panic attacks or other unusual changes in behavior; heart rate, blood pressure and ECG in older adults and patients with preexisting cardiac disease; electrolyte panel (to assess risk of conduction abnormalities); blood glucose; weight and BMI; blood levels are useful for therapeutic monitoring (APA 2010).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133714\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;display:inline\">Therapeutic: Amitriptyline plus nortriptyline 80-250 ng/mL (SI: 288-900 nmol/L); amitriptyline plus nortriptyline levels &gt;300 ng/mL are associated with increased side effects; plasma levels do not always correlate with clinical effectiveness (Am J Psychiatry, 1985; Boyer, 1984; Orsulak, 1979)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133699\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Increases the synaptic concentration of serotonin and/or norepinephrine in the central nervous system by inhibition of their reuptake by the presynaptic neuronal membrane pump.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133720\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: Individual responses may vary; however, 4 to 8 weeks of treatment are needed before determining if a patient with depression is partially or non-responsive; similarly 8 to 12 weeks are required for an adequate migraine prophylaxis trial (APA, 2010; Pringsheim, 2012); desired therapeutic effect (for analgesia) may take as long as 1 to 3 weeks. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Rapid, well absorbed</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: ~18 to 22 L/kg (Schulz, 1985)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: &gt;90% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Rapid; hepatic N to demethylation to nortriptyline (active), hydroxy derivatives and conjugated derivatives </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: ~43% to 46% (Schulz, 1985)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: ~13 to 36 hours (Schulz, 1985)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: ~2 to 5 hours (Schulz, 1985)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (glucuronide or sulfate conjugate metabolites; 18% as unchanged drug); Feces (small amounts)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Special Populations: Elderly: May have increased plasma levels (Schulz, 1985)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133723\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Amitriptyline HCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (100): $31.80</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg (100): $63.60</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (100): $113.14</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">75 mg (100): $190.80</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (100): $254.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150 mg (100): $381.00</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F133726\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Adepril (IT);</li>\n      <li>Adt (PT);</li>\n      <li>Amicon (LK);</li>\n      <li>Amilab (LK);</li>\n      <li>Amilit (IT);</li>\n      <li>Amineurin (DE);</li>\n      <li>Amiprin (JP);</li>\n      <li>Amiram (JO);</li>\n      <li>Amirol (MT);</li>\n      <li>Amirol 25 (ZW);</li>\n      <li>Amitrin-25 (ET);</li>\n      <li>Amitrip (NZ);</li>\n      <li>Amitriptylinum (PL);</li>\n      <li>Amitryl (BD);</li>\n      <li>Amytril (BR);</li>\n      <li>Amyzol (HR);</li>\n      <li>Anapsique (MX);</li>\n      <li>Antalin (CL);</li>\n      <li>Deprelio (ES);</li>\n      <li>Domical (GB);</li>\n      <li>Elatrol (IL);</li>\n      <li>Elatrolet (IL);</li>\n      <li>Elavil (FR);</li>\n      <li>Enafon (KR);</li>\n      <li>Endep (AU, HK);</li>\n      <li>Etravil (KR);</li>\n      <li>Lantron (JP);</li>\n      <li>Laroxyl (BF, BJ, CI, ET, FR, GH, GM, GN, IT, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, VN, ZM, ZW);</li>\n      <li>Miketorin (JP);</li>\n      <li>Modup (TW);</li>\n      <li>Neurotol (PY);</li>\n      <li>Noriline (ZA);</li>\n      <li>Pinsaun (TW);</li>\n      <li>Polytanol (TH);</li>\n      <li>Protanol (BR);</li>\n      <li>Psiquium (CO);</li>\n      <li>Qualitriptine (HK);</li>\n      <li>Redomex (BE);</li>\n      <li>Reptylin (BD);</li>\n      <li>Sarotard (KR);</li>\n      <li>Saroten (BF, BJ, CI, CY, DE, DK, EE, ET, GH, GM, GN, GR, IR, JO, KE, LR, MA, ML, MR, MU, MW, NE, NG, PT, QA, RU, SA, SC, SD, SE, SL, SN, TN, TR, TZ, UA, UG, ZA, ZM, ZW);</li>\n      <li>Saroten Retard (CH, MY);</li>\n      <li>Sarotena (IN);</li>\n      <li>Sarotex (NL, NO, UY);</li>\n      <li>Sarotex Retard (NO);</li>\n      <li>Seronil (BD);</li>\n      <li>Syneudon (DE);</li>\n      <li>Teperin (HU, IQ, JO);</li>\n      <li>Teperinep (HU);</li>\n      <li>Trepiline (ZA);</li>\n      <li>Tridep (BG);</li>\n      <li>Tridep-25 (ZW);</li>\n      <li>Trilin (ID);</li>\n      <li>Trip (BD);</li>\n      <li>Tripgen (PH);</li>\n      <li>Tripta (MY, SG, TH);</li>\n      <li>Triptanol (MX);</li>\n      <li>Triptil (PY);</li>\n      <li>Triptizol (IT);</li>\n      <li>Triptyl (FI);</li>\n      <li>Trynol (TW);</li>\n      <li>Tryptal (ZW);</li>\n      <li>Tryptanol (AR, BR, EC, JP, LK, PE);</li>\n      <li>Tryptizol (AE, AT, BH, CH, EG, ES, GB, JO, KW, LB, NL, PT, SE);</li>\n      <li>Trytomer (IN);</li>\n      <li>Uxen (AR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    ACOG Committee on Practice Bulletins-Obstetrics, &quot;ACOG Practice Bulletin: Clinical Management Guidelines for Obstetrician-Gynecologists Number 92, April 2008 (Replaces Practice Bulletin Number 87, November 2007). Use of Psychiatric Medications During Pregnancy and Lactation,&quot; <i>Obstet Gynecol</i>, 2008, 111(4):1001-20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amitriptyline-drug-information/abstract-text/18378767/pubmed\" target=\"_blank\" id=\"18378767\">18378767</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults [published online October 8, 2015]. <i>J Am Geriatr Soc</i>. 2015;63(11):2227-2246. doi:10.1111/jgs.13702.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amitriptyline-drug-information/abstract-text/26446832/pubmed\" target=\"_blank\" id=\"26446832\">26446832</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Society of Anesthesiologists Task Force on Chronic Pain Management, American Society of Regional Anesthesia and Pain Medicine. Practice guidelines for chronic pain management: an updated report by the American Society of Anesthesiologists Task Force on Chronic Pain Management and the American Society of Regional Anesthesia and Pain Medicine. <i>Anesthesiology</i>. 2010;112(4):810-833.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amitriptyline-drug-information/abstract-text/20124882/pubmed\" target=\"_blank\" id=\"20124882\">20124882</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Geriatrics Society 2012 Beers Criteria Update Expert Panel, &quot;American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,&quot; <i>J Am Geriatr Soc</i>, 2012, 60(4):616-31.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amitriptyline-drug-information/abstract-text/22376048/pubmed\" target=\"_blank\" id=\"22376048\">22376048</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Psychiatric Association (APA). Treatment recommendations for patients with major depressive disorder. 3rd ed. May 2010. Available at http://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd.pdf</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Amitriptyline Hydrochloride [prescribing information]. Chestnut Ridge, NY: Par Pharmaceutical; August 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Andersen PM, Abrahams S, Borasio GD, et al; EFNS Task Force on Diagnosis and Management of Amyotrophic Lateral Sclerosis. EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS)&mdash;revised report of an EFNS task force. <i>Eur J Neurol</i>. 2012;19(3):360-375.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amitriptyline-drug-information/abstract-text/21914052/pubmed\" target=\"_blank\" id=\"21914052\">21914052</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amitriptyline-drug-information/abstract-text/27060684/pubmed\" target=\"_blank\" id=\"27060684\">27060684</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bader TF, Newman K. Amitriptyline in human breast milk and the nursing infant's serum. <i>Am J Psychiatry</i>. 1980;137(7):855-856.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amitriptyline-drug-information/abstract-text/7386673/pubmed\" target=\"_blank\" id=\"7386673\">7386673</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bandelow B, Zohar J, Hollander E, et al, &ldquo;World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders -- First Revision,&rdquo; World J Biol Psychiatry, 2008, 9(4): 248-312. Available at http://www.wfsbp.org/fileadmin/user_upload/Treatment_Guidelines/Guidelines_Anxiety_revision.pdf18949648</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bauer M, Pfennig A, Severus E, Whybrow PC, Angst J, M&ouml;ller HJ; World Federation of Societies of Biological Psychiatry; Task Force on Unipolar Depressive Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders. <i>World J Biol Psychiatry</i>. 2013;14(5):334-385.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amitriptyline-drug-information/abstract-text/23879318/pubmed\" target=\"_blank\" id=\"23879318\">23879318</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bauer M, Whybrow PC, Anst J, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 2: Maintenance treatment of major depressive disorder and treatment of chronic depressive disorders and subthreshold depressions. <i>World J Biol Psychiatry</i>. 2002;3(2):69-86.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amitriptyline-drug-information/abstract-text/12479080/pubmed\" target=\"_blank\" id=\"12479080\">12479080</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Benedek DM, Friedman MJ, Zatzick D, et al, &ldquo;Guideline Watch (March 2009): Practice Guideline for the Treatment of Patients With Acute Stress Disorder and Posttraumatic Stress Disorder.&rdquo; Available at http://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/acutestressdisorderptsd-watch.pdf</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Birmaher B, Brent D, AACAP Work Group on Quality Issues, et al. Practice parameter for the assessment and treatment of children and adolescents with depressive disorders. J Am Acad Child Adolesc <i>Psychiatry</i>. 2007;46(11):1503-1526.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amitriptyline-drug-information/abstract-text/18049300/pubmed\" target=\"_blank\" id=\"18049300\">18049300</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bril V, England J, Franklin GM, et al, &quot;Evidence-Based Guideline: Treatment of Painful Diabetic Neuropathy: Report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation,&quot; <i>Neurology</i>, 2011, 76(20):1758-65.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amitriptyline-drug-information/abstract-text/21482920/pubmed\" target=\"_blank\" id=\"21482920\">21482920</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Boakes AJ, Laurence DR, Teoh PC, et al, &ldquo;Interactions Between Sympathomimetic Amines and Antidepressant Agents in Man,&rdquo; <i>Br Med J</i>, 1973, 1(849):311-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amitriptyline-drug-information/abstract-text/4685619/pubmed\" target=\"_blank\" id=\"4685619\">4685619</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Boyer WF, Friedel RO. Antidepressant and antipsychotic plasma levels. <i>Psychiatr Clin North Am</i>. 1984;7(3):601-610.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amitriptyline-drug-information/abstract-text/6148744/pubmed\" target=\"_blank\" id=\"6148744\">6148744</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"15567552\"></a>Bulut S, Berilgen MS, Baran A, Tekatas A, Atmaca M, Mungen B. Venlafaxine versus amitriptyline in the prophylactic treatment of migraine: randomized, double-blind, crossover study. <i>Clin Neurol Neurosurg</i>. 2004; 107(1):44-48.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amitriptyline-drug-information/abstract-text/15567552/pubmed\" target=\"_blank\" id=\"15567552\">15567552</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Carette S, Bell MJ, Reynolds WJ, et al. Comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia. A randomized, double-blind clinical trial. <i>Arthritis Rheum</i>. 1994;37(1):32-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amitriptyline-drug-information/abstract-text/8129762/pubmed\" target=\"_blank\" id=\"8129762\">8129762</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Couch JR, Ziegler DK, Hassanein R. Amitriptyline in the prophylaxis of migraine: Effectiveness and relationship of antimigraine and antidepressant effects. <i>Neurology</i>. 1976;26(2):121-127.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amitriptyline-drug-information/abstract-text/943066/pubmed\" target=\"_blank\" id=\"943066\">943066</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"2407208\"></a>Davidson J, Kudler H, Smith R, et al. Treatment of posttraumatic stress disorder with amitriptyline and placebo. <i>Arch Gen Psychiatry</i>. 1990;47(3):259-266.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amitriptyline-drug-information/abstract-text/2407208/pubmed\" target=\"_blank\" id=\"2407208\">2407208</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19393844\"></a>Dodick DW, Freitag F, Banks J, et al. Topiramate versus amitriptyline in migraine prevention: a 26 week, multicenter, randomized, double-blind, double-dummy, parallet-group noninferiority trial in adult migraineurs. <i>Clin Ther</i>. 2009;31(3):542-559.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amitriptyline-drug-information/abstract-text/19393844/pubmed\" target=\"_blank\" id=\"19393844\">19393844</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dopheide JA. Recognizing and treating depression in children and adolescents. <i>Am J Health Syst Pharm</i>. 2006;63(3):233-243.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amitriptyline-drug-information/abstract-text/16434782/pubmed\" target=\"_blank\" id=\"16434782\">16434782</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22633628\"></a>Eidlitz-Markus T, Dlugatch Y, Haimi-Cohen Y, Goldberg-Stern H, Zeharia A.. Nonpharmacologic treatment of migraine with low-dose propranolol or amitriptypine. <i>Pediatr Neurol</i>. 2012;46(6):345-349.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amitriptyline-drug-information/abstract-text/22633628/pubmed\" target=\"_blank\" id=\"22633628\">22633628</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Evers S, Afra J, Frese A, et al; European Federation of Neurological Societies. EFNS guidelines on the drug treatment of migraine &ndash; revised report of an EFNS task force. <i>Eur J Neurol</i>. 2009;16(9):968-981.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amitriptyline-drug-information/abstract-text/19708964/pubmed\" target=\"_blank\" id=\"19708964\">19708964</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fava M. Prospective studies of adverse events related to antidepressant discontinuation. <i>J Clin Psychiatry</i>. 2006;67(Suppl 4):14-21.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amitriptyline-drug-information/abstract-text/16683858/pubmed\" target=\"_blank\" id=\"16683858\">16683858</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fortinguerra F, Clavenna A, and Bonati M, &quot;Psychotropic Drug Use During Breastfeeding: A Review of the Evidence,&quot; <i>Pediatrics</i>, 2009, 124(4):547-56.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amitriptyline-drug-information/abstract-text/19736267/pubmed\" target=\"_blank\" id=\"19736267\">19736267</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Foster HE Jr, Hanno PM, Nickel JC, et al; Interstitial Cystitis Collaborative Research Network. Effect of amitriptyline on symptoms in treatment na&iuml;ve patients with interstitial cystitis/painful bladder syndrome. <i>J Urol</i>. 2010;183(5):1853-1858.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amitriptyline-drug-information/abstract-text/20303115/pubmed\" target=\"_blank\" id=\"20303115\">20303115</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Friedlander AH and Mahler ME, &ldquo;Major Depressive Disorder. Psychopathology, Medical Management, and Dental Implications,&rdquo; <i>J Am Dent Assoc</i>, 2001, 132(5):629-38.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amitriptyline-drug-information/abstract-text/11367967/pubmed\" target=\"_blank\" id=\"11367967\">11367967</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Freidrichsdorf SJ, Kang TI. The management of pain in children with life-limiting illnesses. <i>Pediatr Clin N Amer</i>. 2007;54(5):645-672.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amitriptyline-drug-information/abstract-text/17933616/pubmed\" target=\"_blank\" id=\"17933616\">17933616</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ganzberg S, &ldquo;Psychoactive Drugs,&rdquo; <i>ADA Guide to Dental Therapeutics</i>, 2nd ed, Chicago, IL: ADA Publishing, a Division of ADA Business Enterprises, Inc, 2000, 376-405.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"4731336\"></a>Gomersall JD, Stuart A. Amitriptyline in migraine prophylaxis. Changes in pattern of attacks during a controlled clinical trial. <i>J Neurol Neurosurg Psychiatry</i>. 1973;36(4):684-690.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amitriptyline-drug-information/abstract-text/4731336/pubmed\" target=\"_blank\" id=\"4731336\">4731336</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Graff-Radford SB, Shaw LR, Naliboff BN. Amitriptyline and fluphenazine in the treatment of postherpetic neuralgia. <i>Clin J Pain</i>. 2000;16(3):188-192.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amitriptyline-drug-information/abstract-text/11014390/pubmed\" target=\"_blank\" id=\"11014390\">11014390</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Haddad PM. Antidepressant discontinuation syndromes. <i>Drug Saf</i>. 2001;24(3):183-197.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amitriptyline-drug-information/abstract-text/11347722/pubmed\" target=\"_blank\" id=\"11347722\">11347722</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hanno PM, Burks DA, Clemens JQ, et al. American Urological Association guideline: DIagnosis and treatment of interstitial cystitis/bladder pain syndrome. http://www.auanet.org/common/pdf/education/clinical-guidance/IC-Bladder-Pain-Syndrome-Revised.pdf. Updated 2014. Accessed December 9, 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    H&auml;user W, Bernardy K, U&ccedil;eyler N, Sommer C. Treatment of fibromyalgia syndrome with antidepressants: a meta-analysis. <i>JAMA</i>. 2009;301(2):198-209. doi: 10.1001/jama.2008.944.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amitriptyline-drug-information/abstract-text/19141768/pubmed\" target=\"_blank\" id=\"19141768\">19141768</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    H&auml;user W, Wolfe F, T&ouml;lle T, U&ccedil;eyler N, Sommer C. The role of antidepressants in the management of fibromyalgia syndrome: a systematic review and meta-analysis. <i>CNS Drugs</i>. 2012;26(4):297-307. doi: 10.2165/11598970-000000000-00000.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amitriptyline-drug-information/abstract-text/22452526/pubmed\" target=\"_blank\" id=\"22452526\">22452526</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"10940092\"></a>Hershey AD, Powers SW, Bentti AL, et al, &ldquo;Effectiveness of Amitriptyline in the Prophylactic Management of Childhood Headaches,&rdquo; <i>Headache</i>, 2000, 40(7):539-49.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amitriptyline-drug-information/abstract-text/10940092/pubmed\" target=\"_blank\" id=\"10940092\">10940092</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"10891521\"></a>Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amitriptyline-drug-information/abstract-text/10891521/pubmed\" target=\"_blank\" id=\"10891521\">10891521</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jastak JT and Yagiela JA, &ldquo;Vasoconstrictors and Local Anesthesia: A Review and Rationale for Use,&rdquo; <i>J Am Dent Assoc</i>, 1983, 107(4):623-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amitriptyline-drug-information/abstract-text/6355236/pubmed\" target=\"_blank\" id=\"6355236\">6355236</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23406477\"></a>Kalita J, Bhoi Sk, Misra UK. Amitriptyline vs divalproate in migraine prophylaxis: a randomized controlled trial. <i>Acta Neurol Scand</i>. 2013;128(1):65-72.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amitriptyline-drug-information/abstract-text/23406477/pubmed\" target=\"_blank\" id=\"23406477\">23406477</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"2081896\"></a>Kerkhofs M, Rielaert C, de Maertelaer V, Linkowski P, Czarka M, Mendlewicz J. Fluoxetine in major depression: efficacy, safety and effects on sleep polygraphic variables. <i>Int Clin Psychopharmacol</i>. 1990;5(4):253-260.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amitriptyline-drug-information/abstract-text/2081896/pubmed\" target=\"_blank\" id=\"2081896\">2081896</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"18620801\"></a>Keskinbora K, Aydinli I. A double-blind randomized controlled trial of topiramate and amitriptyline either alone or in combination for the prevention of migraine. <i>Clin Neurol Neurosurg</i>. 2008;110(10):979-984.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amitriptyline-drug-information/abstract-text/18620801/pubmed\" target=\"_blank\" id=\"18620801\">18620801</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kliegman RM, Stanton BF, St. Gemell JW, et al, eds. <i>Nelson's Textbook of Pediatrics</i>. 19th ed. Philadelphia, PA: Saunders Elsevier; 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Larsen ER, Damkier P, Pedersen LH, et al. Use of psychotropic drugs during pregnancy and breast-feeding. <i>Acta Psychiatr Scand Suppl</i>. 2015;(445):1-28.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amitriptyline-drug-information/abstract-text/26344706/pubmed\" target=\"_blank\" id=\"26344706\">26344706</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lewis D, Ashwal S, Hershey A, Hirtz D, Yonker M, Silberstein S; American Academy of Neurology Quality Standards Subcommittee; Practice Committee of the Child Neurology Society. Practice parameter: pharmacological treatment of migraine headache in children and adolescents: report of the American Academy of Neurology Quality Standards Subcommittee and the Practice Committee of the Child Neurology Society. <i>Neurology</i>. 2004;63(12):2215-2224.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amitriptyline-drug-information/abstract-text/15623677/pubmed\" target=\"_blank\" id=\"15623677\">15623677</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Macfarlane GJ, Kronisch C, Dean LE, et al. EULAR revised recommendations for the management of fibromyalgia. <i>Ann Rheum Dis</i>. 2017;76(2):318-328. doi: 10.1136/annrheumdis-2016-209724.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amitriptyline-drug-information/abstract-text/27377815/pubmed\" target=\"_blank\" id=\"27377815\">27377815</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Max MB, Schafer SC, Culnane M, Smoller B, Dubner R, Gracely RH. Amitriptyline, but not lorazepam, relieves postherpetic neuralgia. <i>Neurology</i>. 1988;38(9):1427-1432.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amitriptyline-drug-information/abstract-text/3412591/pubmed\" target=\"_blank\" id=\"3412591\">3412591</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"1519713\"></a>McQuay HJ, Carroll D, Glynn CJ. Low dose amitriptyline in the treatment of chronic pain. <i>Anaesthesia</i>. 1992;47(8):646-652.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amitriptyline-drug-information/abstract-text/1519713/pubmed\" target=\"_blank\" id=\"1519713\">1519713</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Miaskowski C, Bair M, Chou R, et al, eds. <i>Principles of Analgesic Use in the Treatment of Acute Pain and Cancer Pain</i>. 6th ed. Glenview, IL: American Pain Society; 2008.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Collaborating Centre for Mental Health (NCCMH). Depression: The Treatment and Management of Depression in Adults (Updated Edition). National Institute for Health &amp; Clinical Excellence (NICE). 2010.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amitriptyline-drug-information/abstract-text/22132433/pubmed\" target=\"_blank\" id=\"22132433\">22132433</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nelson JC, Devanand DP. A systematic review and meta-analysis of placebo-controlled antidepressant studies in people with depression and dementia. <i>J Am Geriatr Soc</i>. 2011;59(4):577-585.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amitriptyline-drug-information/abstract-text/21453380/pubmed\" target=\"_blank\" id=\"21453380\">21453380</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nishishinya B, Urr&uacute;tia G, Walitt B, et al. Amitriptyline in the treatment of fibromyalgia: a systematic review of its efficacy. <i>Rheumatology (Oxford)</i>. 2008;47(12):1741-1746. doi: 10.1093/rheumatology/ken317.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amitriptyline-drug-information/abstract-text/18697829/pubmed\" target=\"_blank\" id=\"18697829\">18697829</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Orsulak PJ, Schildkraut JJ. Guidelines for therapeutic monitoring of tricylic antidepressant plasma levels. <i>Thera Drug Monit</i>. 1979;1(2):199-208.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amitriptyline-drug-information/abstract-text/555572/pubmed\" target=\"_blank\" id=\"555572\">555572</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Page RL 2nd, O'Bryant CL, Cheng D, et al; American Heart Association Clinical Pharmacology and Heart Failure and Transplantation Committees of the Council on Clinical Cardiology; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research. Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association [published correction appears in <i>Circulation</i>. 2016;134(12):e261]. <i>Circulation</i>. 2016;134(6):e32-e69.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amitriptyline-drug-information/abstract-text/27400984/pubmed\" target=\"_blank\" id=\"27400984\">27400984</a>]</span><span class=\"doi\">10.1161/CIR.0000000000000426</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pass SE, Simpson RW. Discontinuation and reinstitution of medications during the perioperative period. <i>Am J Health Syst Pharm</i>. 2004;61:899-914.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amitriptyline-drug-information/abstract-text/15156966/pubmed\" target=\"_blank\" id=\"15156966\">15156966</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pharmacy Quality Alliance. Use of high-risk medications in the elderly (HRM). http://pqaalliance.org/images/uploads/files/HRM2015.pdf. Published 2015. Accessed October 26, 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"6757842\"></a>Pilowsky I, Hallett EC, Bassett DL, Thomas PG, Penhall RK. A controlled study of amitriptyline in the treatment of chronic pain. <i>Pain</i>. 1982;14(2):169-179.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amitriptyline-drug-information/abstract-text/6757842/pubmed\" target=\"_blank\" id=\"6757842\">6757842</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Praharaj SK, Arora M. Amitriptyline for clozapine-induced nocturnal enuresis and sialorrhoea. <i>Br J Clin Pharmacol</i>. 2007;63(1):128-129.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amitriptyline-drug-information/abstract-text/16939528/pubmed\" target=\"_blank\" id=\"16939528\">16939528</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pringsheim T, Davenport W, Mackie G, et al, &quot;Canadian Headache Society Guideline for Migraine Prophylaxis,&quot; <i>Can J Neurol Sci</i>, 2012, 39(2 Suppl 2):S1-59.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amitriptyline-drug-information/abstract-text/22683887/pubmed\" target=\"_blank\" id=\"22683887\">22683887</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rabenda V, Nicolet D, Beaudart C, et al. Relationship between use of antidepressants and risk of fractures: a meta-analysis. <i>Osteoporos Int</i>. 2013;24(1):121-137.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amitriptyline-drug-information/abstract-text/22638709/pubmed\" target=\"_blank\" id=\"22638709\">22638709</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rajagopalan M, Kurian G, John J. Symptom relief with amitriptyline in the irritable bowel syndrome. <i>J Gastroenterol Hepatol</i>. 1998;13(7):738-741.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amitriptyline-drug-information/abstract-text/22638709/pubmed\" target=\"_blank\" id=\"22638709\">22638709</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rizzoli R, Cooper C, Reginster JY, et al. Antidepressant medications and osteoporosis. <i>Bone</i>. 2012;51(3):606-613.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amitriptyline-drug-information/abstract-text/22659406/pubmed\" target=\"_blank\" id=\"22659406\">22659406</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rowbotham MC, Reisner LA, Davies PS, Fields HL. Treatment response in antidepressant-na&iuml;ve postherpetic neuralgia patients: double-blind, randomized trial. <i>J Pain</i>. 2005;6(11):741-746.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amitriptyline-drug-information/abstract-text/16275598/pubmed\" target=\"_blank\" id=\"16275598\">16275598</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rundegren J, van Dijken J, M&ouml;rnstad H, et al, &ldquo;Oral Conditions in Patients Receiving Long-Term Treatment With Cyclic Antidepressant Drugs,&rdquo; <i>Swed Dent J</i>, 1985, 9(2):55-64.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amitriptyline-drug-information/abstract-text/3925584/pubmed\" target=\"_blank\" id=\"3925584\">3925584</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schatzberg AF, Blier P, Delgado PL, et al. Antidepressant discontinuation syndrome: consensus panel recommendations for clinical management and additional research. <i>J Clin Psychiatry</i>. 2006;67(Suppl 4):27-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amitriptyline-drug-information/abstract-text/16683860/pubmed\" target=\"_blank\" id=\"16683860\">16683860</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schulz P, Dick P, Blaschke TF, Hollister L. Discrepancies between pharmacokinetic studies of amitriptyline. <i>Clin Pharmacokinet</i>. 1985;10(3):257-268.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amitriptyline-drug-information/abstract-text/6825390/pubmed\" target=\"_blank\" id=\"6825390\">6825390</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shelton, RC. Steps Following Attainment of Remission: Discontinuation of Antidepressant Therapy. <i>Prim Care Companion J Clin Psychiatry</i>. 2001;3(4):168-174.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amitriptyline-drug-information/abstract-text/15014601/pubmed\" target=\"_blank\" id=\"15014601\">15014601</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Silberstein SD, Holland S, Freitag F, et al, &ldquo;Evidence-Based Guideline Update: Pharmacologic Treatment for Episodic Migraine Prevention in Adults: Report of the Quality Standard Subcommittee of the American Academy of Neurology and the American Headache Society,&rdquo;<i> Neurology</i>, 2012, 78(17):1337-45.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amitriptyline-drug-information/abstract-text/22529202/pubmed\" target=\"_blank\" id=\"22529202\">22529202</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sinha S, Simlai J, Praharaj SK. Very Low Dose Amitriptyline for Clozapine-Associated Sialorrhea. <i>Curr Drug Saf</i>. 2016;11(3):262-263.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amitriptyline-drug-information/abstract-text/27113954/pubmed\" target=\"_blank\" id=\"27113954\">27113954</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Squires N, Wills A, Rowson J. The management of drooling in adults with neurological conditions. <i>Curr Opin Otolaryngol Head Neck Surg</i>. 2012;20(3):171-176. doi: 10.1097/MOO.0b013e32835328ec.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amitriptyline-drug-information/abstract-text/22487791/pubmed\" target=\"_blank\" id=\"22487791\">22487791</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"26204124\"></a>Sriraman NK, Melvin K, Meltzer-Brody S. ABM Clinical Protocol #18: use of antidepressants in breastfeeding mothers. <i>Breastfeed Med</i>. 2015;10(6):290-299.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amitriptyline-drug-information/abstract-text/26204124/pubmed\" target=\"_blank\" id=\"26204124\">26204124</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"9543313\"></a>Srisurapanont M, Jarusuraisin N. Amitriptyline vs. lorazepam in the treatment of opiate-withdrawal insomnia: a randomized double-blind study. <i>Acta Psychiatr Scand</i>. 1998;97(3):233-235.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amitriptyline-drug-information/abstract-text/9543313/pubmed\" target=\"_blank\" id=\"9543313\">9543313</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stevens DL. Association between selective serotonin-reuptake inhibitors, second-generation antipsychotics, and neuroleptic malignant syndrome. <i>Ann Pharmacother</i>, 2008;42(9):1290-1297.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amitriptyline-drug-information/abstract-text/18628446/pubmed\" target=\"_blank\" id=\"18628446\">18628446</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tricyclic antidepressants&mdash;blood level measurements and clinical outcome: an APA Task Force report. Task Force of the Use of Laboratory Tests in Psychiatry. <i>Am J of Psychiatry</i>. 1985;142(2):155-162.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amitriptyline-drug-information/abstract-text/3881999/pubmed\" target=\"_blank\" id=\"3881999\">3881999</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Uguz F. Poor feeding and severe sedation in a newborn nursed by a mother on a low dose of amitriptyline. <i>Breastfeed Med</i>. 2017;12:67-68.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amitriptyline-drug-information/abstract-text/27870551/pubmed\" target=\"_blank\" id=\"27870551\">27870551</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ursano RJ, Bell C, Eth S, et al; Work Group on ASD and PTSD, Steering Committee on Practice Guidelines. Practice guideline for the treatment of patients with acute stress disorder and posttraumatic stress disorder. <i>Am J Psychiatry</i>. 2004;161(11 suppl):3-31.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amitriptyline-drug-information/abstract-text/15617511/pubmed\" target=\"_blank\" id=\"15617511\">15617511</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vahedi H, Merat S, Momtahen S, et al. Clinical trial: the effect of amitriptyline in patients with diarrhoea-predominant irritable bowel syndrome. <i>Aliment Pharmacol Ther</i>. 2008;27(8):678-684.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amitriptyline-drug-information/abstract-text/18248658/pubmed\" target=\"_blank\" id=\"18248658\">18248658</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wagner KD. Pharmacotherapy for major depression in children and adolescents. <i>Prog Neuropsychopharmacol Biol Psychiatry</i>. 2005;29(5):819-826.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amitriptyline-drug-information/abstract-text/15908090/pubmed\" target=\"_blank\" id=\"15908090\">15908090</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Warner, CH, Bobo W, Warner C, et al. Antidepressant discontinuation syndrome. <i>Am Fam Physician</i>. 2006;74:449-456.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amitriptyline-drug-information/abstract-text/16913164/pubmed\" target=\"_blank\" id=\"16913164\">16913164</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Watson CP, Chipman M, Reed K, Evans RJ, Birkett N. Amitriptyline versus maprotiline in postherpetic neuralgia: a randomized, double-blind, crossover trial. <i>Pain</i>. 1992;48(1):29-36.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amitriptyline-drug-information/abstract-text/1738571/pubmed\" target=\"_blank\" id=\"1738571\">1738571</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Watson CP, Evans RJ, Reed K, et al. Amitriptyline versus placebo in postherpetic neuralgia. <i>Neurology</i>. 1982;32(6):671-673.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amitriptyline-drug-information/abstract-text/6283422/pubmed\" target=\"_blank\" id=\"6283422\">6283422</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Watson CP, Vernich L, Chipman M, Reed K. Nortriptyline versus amitriptyline in postherpetic neuralgia: a randomized trial. <i>Neurology</i>. 1998;51(4):1166-1171.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amitriptyline-drug-information/abstract-text/9781549/pubmed\" target=\"_blank\" id=\"9781549\">9781549</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. Available at http://www.who.int/maternal_child_adolescent/documents/55732/en/</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yagiela JA, &ldquo;Adverse Drug Interactions in Dental Practice: Interactions Associated With Vasoconstrictors. Part V of a Series,&rdquo; <i>J Am Dent Assoc</i>, 1999, 130(5):701-9.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yonkers KA, Wisner KL, Stewart DE, et al, &quot;The Management of Depression During Pregnancy: A Report From the American Psychiatric Association and the American College of Obstetricians and Gynecologists,&quot; <i>Obstet Gynecol</i>, 2009, 114(3):703-13.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amitriptyline-drug-information/abstract-text/19701065/pubmed\" target=\"_blank\" id=\"19701065\">19701065</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yoshida K, Smith B, Craggs M, Kumar RC. Investigation of pharmacokinetics and of possible adverse effects in infants exposed to tricyclic antidepressants in breast-milk. <i>J Affect Disord</i>. 1997;43(3):225-237.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amitriptyline-drug-information/abstract-text/9186793/pubmed\" target=\"_blank\" id=\"9186793\">9186793</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zeltzer LK, Krane EJ. Pediatric Pain Management. In: Kliegman RM, Stanton BF, St. Gemell JW, et al, eds. <i>Nelson's Textbook of Pediatrics</i>. 19th ed. Philadelphia, PA: Saunders Elsevier; 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"8352668\"></a>Ziegler DK, Hurwitz A, Preskorn S, Hassanein R, Seim J. Propranolol and amitriptyline in prophylaxis of migraine. Pharmacokinetic and therapeutic effects. <i>Arch Neurol</i>. 1993;50(8):825-830.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amitriptyline-drug-information/abstract-text/8352668/pubmed\" target=\"_blank\" id=\"8352668\">8352668</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"2234996\"></a>Zitman FG, Linssen AC, Edelbroek PM, Stijnen T. Low dose amitriptyline in chronic pain: the gain is modest. <i>Pain</i>. 1990; 42(1):35-42.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amitriptyline-drug-information/abstract-text/2234996/pubmed\" target=\"_blank\" id=\"2234996\">2234996</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8605 Version 253.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708615\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F46519250\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F133739\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F133787\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F133743\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F133763\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F133744\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F133745\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F133746\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F133713\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F133696\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F7874280\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F23890541\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F133717\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25475031\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F133796\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F133703\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F133721\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F133700\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F133781\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F133705\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F133708\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F133724\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F133725\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F133710\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F133714\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F133699\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F133720\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F133723\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F133726\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8605|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=amitriptyline-patient-drug-information\" class=\"drug drug_patient\">Amitriptyline: Patient drug information</a></li><li><a href=\"topic.htm?path=amitriptyline-pediatric-drug-information\" class=\"drug drug_pediatric\">Amitriptyline: Pediatric drug information</a></li></ul></div></div>","javascript":null}